STOCKHOLM,SWEDEN – Ascilion AB ("Ascilion"), the leader in dermal interstitial fluid sampling for molecular biomarker research, diagnostics and wearables announced today an investment of SEK 21 million by Lotus One Investment Pte. Ltd. (“Lotus”) in the company.
The investment by Lotus in Ascilion was through the combination of a SEK 21 million directed share issue and an additional purchase of existing shares. The investment positions Lotus as a key shareholder and grants them representation on the Ascilion’s board of directors, with Asmita Dwivedi recently appointed as a board member.
Nirmal Singh, Executive Chairman of Lotus, commented: “Lotus is committed to supporting innovations that promote the democratization of healthcare services, and we believe that Ascilion, through their unique technology, can enable new health monitoring capabilities as well as improve the accessibility and equity of diagnostics and monitoring services.”
Simon Grant, CEO of Ascilion, commented: “We are very pleased to welcome Lotus as a major shareholder. We share a common vision that Ascilion’s technology will be central to the development of many point-of-care and wearable diagnostic devices in the future. We look forward to our journey together.”
For further information, visit www.ascilion.com or contact:
Simon Grant, CEO
Tel: +46 72 887 43 99
Email: info@ascilion.com
About Ascilion AB
Ascilion is a global leader in dermal interstitial fluid sampling. Ascilion´s innovative and patented microneedle technology is designed to sample dermal interstitial fluid (dISF), the fluid located between skin cells. This fluid is rich in biomarkers and represents a previously underutilized source of real-time health information. The applications of dISF are extensive, including metabolic health monitoring, stress assessment, reproductive hormone tracking, and drug therapy management. By enabling rapid and reliable access to dISF, Ascilion’s technology is poised to become a key enabler of next-generation diagnostic, wellness testing devices and monitoring products. Its flagship product, PELSA, is painless, quick, easy to use, and leaves no residual marks on the skin. PELSA is available for research, pharmaceutical, and cosmetic testing applications and is currently undergoing medical device approval. Based near Stockholm, Sweden, Ascilion collaborates with selected industrial partners and researchers worldwide.
About Lotus One Investment Pte. Ltd.
Lotus One Investment Pte. Ltd. is a Singapore-based family office established in 2019, specialising in strategic investments across South Asia and Europe. The firm focuses on sectors such as hospitality, healthcare, consumer products, digital technology and industrials. Beyond its investment activities, Lotus One Investment is committed to social impact through the Khetan Foundation (earlier Lotus Life Foundation),established in 2016. Its investment approach encompasses listed equities, venture capital, and private equity, with a particular interest in turnaround opportunities.
STOCKHOLM, SWEDEN – Ascilion AB("Ascilion") the leader in dermal interstitial fluid sampling for biomarker investigation using microneedles will present new research and exhibit at MICRONEEDLES 2025 in Brisbane on the 11th-14thMay.
The theme for the 8th international conference on microneedles is Pathways to Products. The conference is the premier global event within microarray patch technology, focusing on the transformative potential of microneedles within transdermal delivery and extraction, diagnostics and broader healthcare. The conference provides an in-depth review of the latest trends and advances in research, design, development, application, clinical translation and commercialisation of microneedle technology.
Markus Renlund, Founder of Ascilion, commented: ‘We are pleased to be here for the 5th time and to present the results from years of development, research and clinical studies. Our topics will span from basic research ex vivo studies to antigen harvesting for mast cell research within immunology to dermal interstitial fluid sampling studies on heart failure patients within the European project DIGIPREDICT.’
Simon Grant, CEO of Ascilion, continued: ‘I look forward to sharing our commercialization experiences, successes and challenges with the Conference. Ascilion is the pioneer and leader within diagnostic microneedles and as of today we are one of the few companies within this exciting segment.’
Ascilion will together with its clinical partners present on the following topics:
”Hollow silicon microneedles used for extraction of dermal interstitial fluid in heart failure patients within the European project DIGIPREDICT”
”Tissue-specific soluble biomarker profiles in dermal interstitial fluid reveal unique information not detectable in plasma”
“Antigen discovery in cold urticaria using sampled dermal interstitial fluid – a new application area for hollow microneedles”
”Extraction of biomolecules from skin with hollow microneedles and application in ex vivo skin models of chronic inducible urticaria and allergy”
“Commercialization challenges for diagnostic microneedle companies”
”Reliable sampling of dermal interstitial fluid – a driver for application development”
For further information contact:
Simon Grant, CEO
Tel: +46 72 887 43 99
E-post: info@ascilion.com
About Ascilion
Ascilion is the world leader in sampling of dermal interstitial fluid (dISF). A pioneer within hollow microneedle technology, Ascilion has developed the only solution available for sampling of practical amounts of pure dISF, enabling complete quantitative biomarker evaluation. Ascilion’s product PELSA is painless, quick, easy to use and leave sno residual mark on the skin. PELSA is available for research use and for pharmaceutical or cosmetic testing applications and is currently undergoing the medical product approval process. We are a cross-functional team based just outside Stockholm, Sweden and currently work with selected industrial partnersand researchers.
About DIGIPREDICT
DIGIPREDICT – Digital Edge AI-deployed DIGItal Twins for PREDICTing disease progression and need for early intervention in infectious and cardiovascular diseases beyond COVID-19.
DIGIPREDICT is a pan-European researchprogram bringing together scientific and technical excellence in multiple disciplines including informatics, engineering (embedded systems, sensors and wearables), medical science, translational science, ethical and regulatory frameworks. The consortium consists of in total nine members from academia, two large R&D institutes, two hospitals, three high-tech SMEs from five European countries. The project will develop Digital Twins to enable identification, monitoring, and screening of high-risk patients, and to provide them with the right supportive therapy based on referral decisions that can be personalized. A digital twin is a digital representation of an object or process from the real world in the digital world – and more specifically for the case of DIGIPREDICT – of a patient.
DIGIPREDICT will also develop wearables for early detection of infectious and cardiovascular diseases.
Ascilion will attend and exhibit at the 8th Annual Dermatology Drug Development Summit for Inflammatory Skin Disease in Boston. The meeting will be held from the 12th-14th November 2024
The conference is specifically for executives from pharmaceutical companies working within drug development in the inflammatory skin disease area. This will be an excellent opportunity for Ascilion to discuss the expanding list of applications for dermal interstitial fluid (dISF) sampling technology within pharmaceutical development.
For more information see: https://dermatology-drugdevelopment.com/
